This first RCT of hypertonic saline use in pediatric non-CF bronchiectasis patients uses a cross over design and demonstrates an improvement in predicted FEV1 and FVC. Limitations include lack of blinding and risk of information bias, as well as reduced precision due to absence of within subject comparisons.
